Questcor Pharmaceuticals — JP Morgan Healthcare Conference 2012
30 slides from Questcor Pharmaceuticals's conference presentation, Jan 9, 2012
Slide 1: January 2012 JP Morgan Healthcare Conference
January 2012 JP Morgan Healthcare Conference Exhibit 99.2 January 2012 JP Morgan Healthcare Conference
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement Except for the historical information contained herein, this presentation contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to
Slide 3: Questcor: A biopharmaceutical company whose product, Acthar, helps patients
3 A biopharmaceutical company whose product, Acthar, helps patients with serious, difficult-to-treat medical conditions Questcor A biopharmaceutical company whose product, Acthar, helps patients with serious, difficult-to-treat medical conditions
Slide 4: Questcor Overview
4 Questcor Overview Flagship Product: • Profitable, cash flow positive, $209M* in cash, debt-free • 19 approved indications Key Markets: • Multiple Sclerosis, Nephrotic Syndrome, Infantile Spasms • Several billion dollar market opportunity Strategy: • Grow Acthar sales in each key market • Develop o
Slide 5: Questcor Strategy - Pursue Acthar Markets
Multiple Sclerosis (MS) Nephrotic Syndrome (NS) Infantile Spasms (IS) Systemic Lupus Erythematosus Questcor Strategy - Pursue Acthar Markets 5 Multiple Sclerosis (MS) Nephrotic Syndrome (NS) Infantile Spasms (IS) Systemic Lupus Erythematosus
Slide 6: Acthar and Multiple Sclerosis (MS)
Acthar and Multiple Sclerosis (MS) Neurodegenerative disorder Acute treatment for relapses 43% get better or much better 27% get only a little better 30% stay the same or get worse 6 *Nickerson, et al ( 2011) Neurodegenerative disorder Acute treatment for relapses Potential target for 43% get better
Slide 7: MS Scripts - Record of Consistent Growth
7 Paid Rxs MS Scripts-Record of Consistent Growth Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is th
Slide 8: Monthly MS Scripts History
8 Monthly MS Scripts History Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the focus of the chart.
Slide 9: Acthar and Nephrotic Syndrome (NS)
• Characterized by excessive spilling of protein from the kidneys into the urine (proteinuria) • Can result in end-stage renal disease (ESRD), dialysis, transplant • Significant unmet need – Few treatment options – Goal of therapy is the significant reduction of proteinuria Acthar and Nephrotic Synd
Slide 10: NS Scripts - Strong Q4 Growth
10 Paid Rxs NS Scripts-Strong Q4 Growth Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the focus of
Slide 11: Acthar and Infantile Spasms (IS)
11 • FDA approval 10/15/10 • Devastating, refractory form of childhood epilepsy • IS not responsive to standard anti-epileptic drugs • Unsuccessful treatment may leave infant with permanent developmental disabilities • Considered a medical emergency • Ultra-rare orphan disorder • About half of IS pa
Slide 12: IS Scripts - Higher numbers in H2 2011
12 IS Scripts-Higher numbers in H2 2011 • Acthar currently used to treat 40-50% of IS patients • Targeting select institutions • Significant variability in quarterly Rxs • Q4-2011 paid Rxs above historic range
Slide 13: Systemic Lupus Erythematosus (Lupus)
13 • High unmet need; difficult to treat • Serious health risk if unsuccessfully treated • Multiple on-label indications for Acthar – Exacerbations – Maintenance therapy – Lupus nephritis • Large patient population Systemic Lupus Erythematosus (Lupus) • High unmet need; difficult to treat • Serious
Slide 14: Financials
14 Financials Profitable Debt Free Cash Flow Positive Profitable Debt Free Cash Flow Positive
Slide 15: Q3-2011 Financial Results
15 Q3 – 2011 Q3 – 2010 Q3-2011 Financial Results • Third quarter vials shipped: 2,910 • Third quarter cash flow from operations: $32.6M • Channel inventory estimated to be within historic range • Medicaid reserves continue to appear adequate • No shares repurchased Record Net Sales (up 91%) and Soli
Slide 16: Questcor is Cash Flow Positive, Debt-free Balance Sheet
16 01/04/12 Questcor is Cash Flow Positive Debt-free balance sheet *After return of $78 million of cash to shareholders through share repurchases. 16 Cash / ST Investments $209M* Accounts Receivable $28M Debt-free balance sheet *After return of $78 million of cash to shareholders through share repur
Slide 17: Share Repurchases: 15 Million Shares
17 • 2.2 Million Preferred share buyback • 13.2 Common share buyback • $78 million returned to shareholders in stock buybacks • 63.6 million shares currently outstanding • 4.3 million shares remain on buyback authorization Share Repurchases: 15 Million Shares Repurchased shares significantly improve
Slide 18: Preliminary Q4-2011 Operating Metrics
18 • Paid Rxs (Approximate) – MS—935-950 • October 295-300 • November 320-325 • December 320-325 – NS—140-150 – IS—120-125 • 3,360 Vials Shipped • Operating expenses expected to be up 20-30% from Q3-2011 Preliminary Q4-2011 Operating Metrics • Paid Rxs (Approximate) – MS—935-950 • October 295-300 •
Slide 19: How Does Acthar Work?
19 How Does Acthar Work? • Acthar treats autoimmune conditions across a variety of organ systems (CNS, kidney, etc.) • Acthar appears to modulate the immune system and associated inflammatory response through binding to melanocortin receptors • The primary melanocortin peptide (ACTH) in Acthar binds
Slide 20: Competitive Pathways
20 Generic Pathway Requires reverse engineering -- a difficult barrier Must prove pharmaceutical & biological equivalence Immune system impact unknown New Chemical Entity or Biosimilar Pathway Trial(s) required Limited exclusivity Results in duopoly SUBSTITUTABILITY SINGLE INDICATION COMPETITION Com
Slide 21: Acthar Market Opportunity
21 Acthar Market Opportunity Market Rx Value Market Size Total $2B+ MS $40-50K $1B+ NS $150-250K $1B+ IS $100-125K $100M Lupus Unknown Unknown Other Various Unknown
Slide 22: Annualized Net Sales Run Rate by Market
22 Market Approximate Annualized Net Sales Run Rate* Approximate Annualized Level of Business** NS Business Already Significant MS $145-160M $145-160M NS $60-70M $100-110M IS $40-50M $40-50M Note: Figures do not based on actual net sales ranges for the quarter or year ended December 31, 2011 * Figur
Slide 23: Strategic Plan - Focus on the Embedded Pipeline in Acthar
23 • Expand NS promotion effort • Expand MS promotion effort • Maintain IS promotion effort • Develop pilot rheumatology promotion activity • Develop other markets for Acthar Acthar is its own pipeline with many other on-label indications and many possible other therapeutic uses Further define and d
Slide 24: Sales Force Expansion - Preliminary Outlook for 2012
24 Sales Force Expansion- Preliminary Outlook for 2012 Q1-12 Q2 Q3 Q4 Q1-13 Possible Rheumatology Possible Rheumatology Sales Pilot Sales Pilot Neuro Hiring & Neuro Hiring & Training Training Neuro Neuro Sizing & Sizing & Alignment Alignment Neph Hiring & Neph Hiring & Training Training Neph Sizing
Slide 25: Investment Highlights
25 Investment Highlights Acthar has sustainable competitive Acthar has sustainable competitive advantages-without FDA approval risk advantages-without FDA approval risk Acthar is approved for 19 indications-many Acthar is approved for 19 indications-many in large markets with sizable unmet need in l
Slide 26: January 2012 JP Morgan Healthcare Conference
NASDAQ: QCOR January 2012 JP Morgan Healthcare Conference NASDAQ: QCOR
Slide 27: ACTH is a Melanocortin Peptide Derived from POMC in the Pituitary
27 ACTH is a Melanocortin Peptide Derived from Pro-opiomelanocortin (POMC) in the Pituitary
Slide 28: Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes
28 MCR Prevalent Tissue/Cells with Receptor Adapted from Gong 2011, Catania 2004, Schioth 1997 Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes MC1R Podocytes Renal Mesangial Cells Endothelial Cells (Glomerular, Tubular, Vascular) Tubular Epithelial Cells Macrophages Melanocyt
Slide 29: Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes (cont.)
29 MCR Prevalent Tissue/Cells with Receptor Adapted from Gong 2011, Catania 2004, Schioth 1997 Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes MC3R CNS Macrophages MC4R Podocytes Renal Mesangial Cells (?) Endothelial Cells (Glomerular, Tubular) Tubular Epithelial Cells CNS MC
Slide 30: MOA of Acthar in NS
30 MOA of Acthar in NS Adapted From Gong 2011 Acthar, Melanocortin Peptides Acthar, Melanocortin Peptides
Questcor Pharmaceuticals — JP Morgan Healthcare Conference 2012 on 6ix